Compass Pathways issues 8-K detailing clinical and regulatory risks
Compass Pathways filed an exhibit containing forward-looking statement risks regarding clinical trials and funding needs. This standard legal disclosure outlines potential delays or uncertainties that may impact the company's development pipeline.
View filing at SEC.gov →